Overview of cystinuria Overview of cystinuria

Rare, lifelong, genetic disorder: cystinuria requires ongoing management2,3

Cystinuria is a rare condition characterized by lifelong, recurrent stones that are difficult to manage.2 Defective amino acid transporters in the proximal tubules of the kidney result in elevated urinary cystine concentration, and when these cystine levels rise above the solubility limit (generally 250 mg/L), cystine stones form.4 

Cystine stones are typically harder, larger, and occur more frequently than other kidney stones. Cystine stones often result in significant pain and morbidity.5

If cystinuria is suspected, the American Urological Association recommends metabolic testing consisting of one or two 24-hour urine collections obtained on a random diet and analyzed at minimum for total volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, and creatinine.6

In addition to using a 24-hour urine test, diagnostic-related guidelines recommend6:

Obtaining a stone analysis at least once.

Obtaining or reviewing available imaging studies to quantify stone burden.

Performing additional metabolic testing in high-risk or interested patients with a first-time stone and those with recurrent stones.

Medical bag

Failure to prevent cystine stones has been demonstrated approximately 55% of the time.7

  • High fluid intake, alkali, and diet modification alone may not be enough to control cystine.1,7
  • In a clinical trial of 27 patients with cystinuria managed by high fluid intake and alkalization, 15 patients failed to manage their condition on these methods alone.7

About THIOLA EC

Early recognition Early recognition

Stone prevention begins with early recognition of cystine buildup

Regular monitoring enables early detection so you can take action at the first sign of cystine buildup. The following are indicators that you may need to modify your patients’ management plans: 

Sand/gravel in urine2

24-hour urine test results showing elevated cystine levels6,8

Imaging showing presence of stones9

Kidney stone-related pain8

Taking THIOLA EC at the right dosage increases the solubility of cystine in the urine. THIOLA EC should be dosed to effect on the results of a 24-hour urine test.
Optimize the THIOLA EC dosage needed to reduce cystine below its solubility limit, generally <250 mg/L.1

THIOLA EC dosing

AUA Kidney Stone Guidelines

A summary of evidence-based recommendations from the American Urological Association (AUA) on the medical management of cystine stones.

AUA Guidelines
Managing cystinuria Managing cystinuria

Goal of cystinuria management

Due to cystinuria being a genetic and lifelong disorder, cystine stones are constantly forming as a result of cystine buildup.2,3 Patients are always under the threat of recurring cystine stones. It is therefore critical to develop a treatment plan focused on prevention.4

Stone prevention by lowering urinary cystine concentration generally to <250 mg/L1,4

Avoiding and/or minimizing invasive procedures4,9

Keeping kidneys working normally to prevent long-term damage2

Magnifying glass

Encourage your patients to ask you questions about these goals and provide them with access to educational resources.

Connect to resources

Follow the recommended guidelines for stone prevention

Increasing water intake helps dilute cystine in the urine.10

TARGET: A minimum urine output of 2.5 L/day on a consistent basis6

HOW TO ACHIEVE: Talk to your patients about targeting a daily fluid intake of 4 L6

Reducing sodium and animal protein in the diet reduces the amount of cystine in the urine.10

TARGET: A diet low in sodium and animal protein10

HOW TO ACHIEVE: A reasonable goal for sodium intake is ≤100 mEq (2300 mg/day)6

Maintaining a urinary pH level of 7.0 increases the solubility of cystine in the urine.6

TARGET: A urine pH level of 7.06

HOW TO ACHIEVE: This is often made possible by taking potassium alkali6

Along with these measures, taking THIOLA EC at the right dosage increases the solubility of cystine in the urine.1

TARGET: The optimal THIOLA EC dosage needed to reduce cystine below its solubility limit, generally <250 mg/L1

  • In adults, the recommended starting dosage is 800 mg/day.1
  • In children ≥20 kg, the recommended starting dose is 15 mg/kg/day.1

Adjust these measures to optimize treatment plans for each patient

Individualized management plans for each patient can help prevent the next stone

 

Develop personalized management plans for each patient to help prevent the next stone

When you see an indicator of cystine buildup, don’t wait to make management plan changes—take action immediately.

Cystinuria management requires a combination of measures to reduce cystine buildup and remove excess cystine from the body.10,11 Keep in mind that adjustments to management plans should be individualized based on reducing cystine below its solubility limit, generally <250 mg/L.4

Stone prevention requires proactive partnership with your patients

While a comprehensive management approach can optimize outcomes, ensuring that patients adhere to their management plans will help them be successful.1,4,8

EDUCATE

patients about how these indicators may require adjustments to their management plans.

MONITOR

routinely, using 24-hour urine testing and imaging to see how cystine levels are responding to treatment.2

DISCUSS

the importance of compliance to help prevent the next stone event.

While current procedures can help remove existing kidney stones (e.g., ureteroscopy, percutaneous nephrolithotomy, and open surgery), they do not treat the underlying disease and are ineffective at preventing future stone formations2,10

Shield

Learn about the free Cystinuria Management Program to help monitor your patient's risk of forming stones. Enrollment provides patients access to free 24-hour urine cystine testing.

 

Learn more

*Free to patients diagnosed with cystinuria.

Important fast facts Important fast facts

Cystinuria can pose unique and significant challenges that are distinct from those associated with the more common kidney stones.5 Below are some fast facts about cystinuria that make this disease particularly difficult to manage.

It has been reported that patients experience an average of 1 stone formation per year.7

Up to 70% of patients experience long-term kidney disease.2

Patients undergo an average of 1 surgical procedure every 3 years, with 7 surgical procedures by middle age.7,12

About 1 in 10,000 people in the United States live with cystinuria.13

More than 80% of people with cystinuria develop cystine kidney stones by age 20.14

Cystinuria is the cause of approximately 10% of all kidney stones in children.10

References:  1. THIOLA EC [package insert]. San Antonio, TX: Mission Pharmacal Company.  2. Biyani et al. EAU-EBU Update Series. 2006;4(5):175-183.  3. Parr et al. BJU Int. 2015;116(suppl 3):31-35.  4. Pareek et al. J Urol. 2005;174(6):2250-2252.  5. Modersitzki et al. Urolithiasis. 2014;42(1):53-60.  6. Pearle et al. J Urol. 2014;192(2):316-324.  7. Barbey et al. J Urol. 2000;163(5):1419-1423.  8. What are cystine stones? The National Kidney Foundation website. https://www.kidney.org/atoz/content/what-are-cystine-stones. Published March 8, 2016. Accessed January 10, 2019.  9. Claes et al. Pediatr Nephrol. 2012;27(11):2031-2038.  10. Knoll et al. Pediatr Nephrol. 2005;20(1):19-24.  11. Andreassen et al. Urolithiasis. 2016;44(1):65-76.  12. Goodyer. Nephron Exp Nephrol. 2004;98(2):e45-e49.  13. Cystinuria. Genetics Home Reference website. https://ghr.nlm.gov/condition/cystinuria. Published December 13, 2016. Accessed December 15, 2016.  14. Eggermann et al. Orphanet J Rare Dis. 2012;7:19.

THIOLA EC® (tiopronin, delayed-release tablets)

INDICATIONS AND USAGE: THIOLA EC® (tiopronin, delayed-release tablets) is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients ≥20 kg with severe homozygous cystinuria, who are not responsive to these measures alone.

Important Safety Information

CONTRAINDICATIONS: THIOLA EC is contraindicated in patients with hypersensitivity to tiopronin or any other components of THIOLA EC.

WARNINGS AND PRECAUTIONS:

  • Proteinuria: Proteinuria, including nephrotic syndrome, and membranous nephropathy, has been reported with tiopronin use. Pediatric patients receiving >50 mg/kg of tiopronin per day may be at increased risk for proteinuria. Monitor patients for the development of proteinuria and discontinue therapy in patients who develop proteinuria.
  • Hypersensitivity Reactions: Hypersensitivity reactions (drug fever, rash, fever, arthralgia and lymphadenopathy) have been reported.

ADVERSE REACTIONS: The most common adverse reactions (≥10%) are nausea, diarrhea or soft stools, oral ulcers, rash, fatigue, fever, arthralgia, proteinuria, and emesis.

DRUG INTERACTIONS: Avoid alcohol consumption 2 hours before and 3 hours after taking THIOLA EC as THIOLA EC is released faster in the presence of alcohol.

SPECIFIC POPULATIONS:

  • Lactation: Breastfeeding is not recommended during treatment with THIOLA EC.
  • Geriatric Use: Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

You may report negative side effects to Travere Therapeutics Medical Information at 1-877-659-5518, or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information for additional Important Safety Information.

 

THIOLA® (tiopronin tablets)

INDICATIONS AND USAGE: THIOLA® (tiopronin tablets) is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients ≥20 kg with severe homozygous cystinuria, who are not responsive to these measures alone.

Important Safety Information

CONTRAINDICATIONS: THIOLA is contraindicated in patients with hypersensitivity to tiopronin or any other components of THIOLA.

WARNINGS AND PRECAUTIONS:

  • Proteinuria: Proteinuria, including nephrotic syndrome, and membranous nephropathy, has been reported with tiopronin use. Pediatric patients receiving >50 mg/kg of tiopronin per day may be at increased risk for proteinuria. Monitor patients for the development of proteinuria and discontinue therapy in patients who develop proteinuria.
  • Hypersensitivity Reactions: Hypersensitivity reactions (drug fever, rash, fever, arthralgia and lymphadenopathy) have been reported.

ADVERSE REACTIONS: The most common adverse reactions (≥10%) are nausea, diarrhea or soft stools, oral ulcers, rash, fatigue, fever, arthralgia, proteinuria, and emesis.

SPECIFIC POPULATIONS:

  • Lactation: Breastfeeding is not recommended during treatment with THIOLA.
  • Geriatric Use: Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

You may report negative side effects to Travere Therapeutics Medical Information at 1-877-659-5518, or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information for additional Important Safety Information.